Acquisition of imipenem-resistant Acinetobacter baumannii in a pediatric intensive care unit: A case-control study

Intensive Care Medicine

Volumn 32, Issue 9, 2006, Pages 1384-1391

  Katragkou, Aspasia ^a   Kotsiou, Maria ^b   Antachopoulos, Charalampos ^a   Benos, Alexis ^a   Sofianou, Danai ^b   Tamiolaki, Maria ^b   Roilides, Emmanuel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

Author keywords

Acinetobacter baumannii; Imipenem resistant; Pediatric intensive care unit; Risk factors

Indexed keywords

ACICLOVIR; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; METRONIDAZOLE; NETILMICIN; OMEPRAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; SUCRALFATE; TICARCILLIN; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CENTRAL VENOUS CATHETER; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EVALUATION RESEARCH; FEMALE; HEALTH CARE POLICY; HUMAN; IMIPENEM RESISTANT ACINETOBACTER BAUMANNII; INFECTION CONTROL; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; UNIVARIATE ANALYSIS; URINE CATHETER;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; GREECE; HUMANS; IMIPENEM; INTENSIVE CARE UNITS, PEDIATRIC; LENGTH OF STAY; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33747620880     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-006-0239-x     Document Type: Article

References (41)

1. Brun-Buisson C, Meshaka P, Pinton P, Vallet B (2004) EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 30:580-588
2. Richards MJ, Edwards JR, Culver DH, Gaynes RP (1999) Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System Pediatrics 103:e39
3. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639-644
4. Bergogne-Berezin E, Towner KJ (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9:148-165
5. Bonfiglio G, Russo G, Nicoletti G (2002) Recent developments in carbapenems. Expert Opin Investig Drugs 11:529-544
6. Afzal-Shah M, Livermore DM (1998) Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 41:576-577
7. Coelho J, Woodford N, Turton J, Livermore DM (2004) Multiresistant acinetobacter in the UK: how big a threat? J Hosp Infect 58:167-169
8. Livermore DM (2003) The threat from the pink corner. Ann Med 35:226-234
9. Van Looveren M, Goossens H (2004) Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 10:684-704
10. D'Agata EM, Thayer V, Schaffner W (2000) An outbreak of Acinetobacter baumannii: the importance of cross-transmission. Infect Control Hosp Epidemiol 21:588-591
11. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Perez-Paredes C, Barrero-Almodovar AE, Gili-Miner M (2001) Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 33:939-946
12. Fierobe L, Lucet JC, Decre D, Muller-Serieys C, Deleuze A, Joly-Guillou ML, Mantz J, Desmonts JM (2001) An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol 22:35-40
13. Koeleman JG, Parlevliet GA, Dijkshoorn L, Savelkoul PH, Vandenbroucke-Grauls CM (1997) Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J Hosp Infect 37:113-123
14. Wong TH, Tan BH, Ling ML, Song C (2002) Multi-resistant Acinetobacter baumannii on a burns unit-clinical risk factors and prognosis. Burns 28:349-357
15. Smolyakov R, Borer A, Riesenberg K, Schlaeffer F, Alkan M, Porath A, Rimar D, Almog Y, Gilad J (2003) Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 54:32-38
16. Rello J, Diaz E (2003) Acinetobacter baumannii: a threat for the ICU? Intensive Care Med 29:350-351
17. Katragkou A, Kotsiou M, Antachopoulos C, Benos A, Sofianou D, Tamiolaki M, Roilides E (2005) Acquisition of imipenem-resistant Acinetobacter baumannii (IRAB) in a pediatric intensive care unit (PICU): a case control study (abstr 1086) In: 43rd IDSA abstracts, Infectious Disease Society of America, October 2005, pp 239-240
18. Pollack MM, Patel KM, Ruttimann UE (1996) PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med 24:743-752
19. Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW, Woo JH, Ryu J, Kim YS (2004) Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 48:224-228
20. Harris AD, Karchmer TB, Carmeli Y, Samore MH (2001) Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 32:1055-1061
21. Paterson DL (2002) Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis 34:1564-1567
22. Mickey RM, Greenland S (1989) The impact of confounder selection criteria on effect estimation. Am J Epidemiol 129:125-137
23. Katz MH (2003) Multivariable analysis: a primer for readers of medical research. Ann Intern Med 138:644-650
24. Concato J, Feinstein AR, Holford TR (1993) The risk of determining risk with multivariable models. Ann Intern Med 118:201-210
25. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J (2000) Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 31:101-106
26. Mulin B, Talon D, Viel JF, Vincent C, Leprat R, Thouverez M, Michel-Briand Y (1995) Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 14:569-576
27. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, Mosinka-Snipas K, Rahal JJ (1994) Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344:1329-1332
28. del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D, Molina F, Villanueva R, Cisneros JM, Bou G (2005) Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 11:540-546
29. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, Aldabo-Pallas T, Cayuela A, Marquez-Vacaro JA, Garcia-Curiel A, Jimenez-Jimenez FJ (2005) Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 31:649-655
30. Leroy O, d'Escrivan T, Devos P, Dubreuil L, Kipnis E, Georges H (2005) Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms. Infection 33:129-135
31. Gilbert DN (2000) Aminoglycosides-pharmacology In: Mandell GL, Benett JE, Dolin R (eds) Principles and practice of infectious diseases, 5th edn. Churchill Livingstone, New York, pp 317-318
32. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, Ayala JA, Perea EJ, Pascual A (2003) Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 51:565-574
33. Limansky AS, Mussi MA, Viale AM (2002) Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J Clin Microbiol 40:4776-4778
34. Afzal-Shah M, Woodford N, Livermore DM (2001) Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 45:583-588
35. Turner PJ (2005) Extended-spectrum beta-lactamases. Clin Infect Dis 41 [Suppl 4]:273-275
36. Walsh TR, Toleman MA, Poirel L, Nordmann P (2005) Metallo-betalactamases: the quiet before the storm? Clin Microbiol Rev 18:306-325
37. Giamarellou H (2005) Multidrug resistance in Gram-negative bacteria that produce extended-spectrum betalactamases (ESBLs). Clin Microbiol Infect 11:1-16
38. Scerpella EG, Wanger AR, Armitige L, Anderlini P, Ericsson CD (1995) Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case-control and molecular epidemiologic investigations. Infect Control Hosp Epidemiol 16:92-97
39. Wang SH, Sheng WH, Chang YY, Wang LH, Lin HC, Chen ML, Pan HJ, Ko WJ, Chang SC, Lin FY (2003) Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumannii in a surgical intensive care unit. J Hosp Infect 53:97-102
40. Denton M, Wilcox MH, Parnell P, Green D, Keer V, Hawkey PM, Evans I, Murphy P (2004) Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit. J Hosp Infect 56:106-110
41. Simor AE, Lee M, Vearncombe M, Jones-Paul L, Barry C, Gomez M, Fish JS, Cartotto RC, Palmer R, Louie M (2002) An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infect Control Hosp Epidemiol 23:261-267